Biotech Industry · global
Enveda Raises $311 Million to Put AI-Discovered Drugs from Natural Molecules to the Clinical Test
Three drug candidates have entered human trials, and the new funding will support therapies for eczema, weight maintenance and intestinal inflammation. Early signals have attracted capital to natural-molecule discovery, but larger trials are still needed to determine whether they can translate into lasting efficacy.
Finding promising molecules in plants and microbes is only the starting point for drug development; the next step is proving that they can safely improve patients’ lives. Enveda, a U.S. biotech company that uses artificial intelligence to explore natural molecules, announced on September 23, 2026, that it had completed a $311 million Series E financing round, preparing to devote more resources to the journey from laboratory to clinic.
The round was led by Catalio Capital Management, bringing the company’s total funding to more than $845 million. BioSpace described it as a crossover financing round bringing in public-market investors, with participants including Surveyor Capital, investment management teams at T. Rowe Price and Lux Capital. The funding gives Enveda more room to advance trials, but it does not mean efficacy has been confirmed, nor is there a definite timeline for market launch.
Enveda’s discovery tool is its PRISM platform. According to the company, it predicts the structures of molecules found in plants, microbes and the human body from mass spectrometry data, then guides experiments and ranks candidate molecules by therapeutic potential before chemists refine them into compounds suitable for drug development. AI helps narrow the search, while the molecules’ function and safety still require experimental validation. BioPharma Dive reported that the company is evaluating 17 research and development programs originating from this discovery process, with three drug candidates already in human trials.
The funding will support ENV-294 and ENV-308 as they advance into later-stage trials and explore additional indications. The former is being developed for atopic dermatitis and asthma, and the company has reported signals of eczema improvement from a small early-stage trial. The latter is inspired by a natural molecule produced in the human body after exercise and is planned for weight maintenance after discontinuation of GLP-1 drugs. The two address different clinical questions, and each needs to establish its own evidence of efficacy.
For ENV-308, the data released so far come mainly from a Phase 1 trial in healthy volunteers; preliminary tolerability findings cannot directly answer whether patients can maintain their weight loss. The early symptom improvements seen with ENV-294 likewise require larger studies with appropriate controls and longer follow-up to determine whether the effects are reliable and to assess the risks of long-term treatment.
Another oral drug candidate, ENV-6946, which targets inflammatory bowel disease, is also included in the funding plans. The company’s announcement stated that it would advance the candidate’s mid-stage clinical development and bring other candidates for inflammatory and metabolic diseases into human trials. Some of the funding will also be used to expand PRISM and the automated laboratories that supply experimental data. These are development plans presented at the time of the financing and should not be taken to mean that trials have already been completed or succeeded.
For Enveda, this financing round allows natural-molecule discovery and clinical development to expand in parallel. However, the available announcements do not provide complete data sufficient to independently compare PRISM with traditional methods in terms of success rates, costs or speed. None of the three clinical candidates had been approved at the time of the announcement; the real test of this AI drug discovery approach will be whether subsequent trials deliver reproducible benefits for patients.